Quick Answer
Foghorn Therapeutics Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $30.91 million for the year ending 2025.
- Foghorn Therapeutics Inc. showed an increase of +36.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Foghorn Therapeutics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 7,088.1%.
- Historical annual values: Fiscal year 2025: $30.91 million | Fiscal year 2024: $22.60 million | Fiscal year 2023: $34.16 million | Fiscal year 2022: $19.23 million | Fiscal year 2021: $1.32 million | Fiscal year 2020: $430.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: